163 related articles for article (PubMed ID: 34689317)
1. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
[TBL] [Abstract][Full Text] [Related]
2. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
3. Prediction of thyroid hormone supplementation after thyroid lobectomy.
Lee DY; Seok J; Jeong WJ; Ahn SH
J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
[TBL] [Abstract][Full Text] [Related]
4. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
5. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
Dou Y; Chen Y; Hu D; Su X
Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
[TBL] [Abstract][Full Text] [Related]
6. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
7. 2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.
Reed R; Strumpf A; Martz TG; Kavanagh KJ; Fedder KL; Jameson MJ; Shonka DC
Head Neck; 2021 Feb; 43(2):639-644. PubMed ID: 33124116
[TBL] [Abstract][Full Text] [Related]
8. Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma.
Ahn D; Lee GJ; Sohn JH; Jeon JH
Head Neck; 2020 May; 42(5):1004-1013. PubMed ID: 31930773
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up.
Kim SY; Kim HJ; Kim SM; Chang H; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():520. PubMed ID: 32849303
[No Abstract] [Full Text] [Related]
10. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract][Full Text] [Related]
11. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.
Park JH; Lee YM; Lee YH; Hong SJ; Yoon JH
J Surg Oncol; 2018 Sep; 118(3):390-396. PubMed ID: 30114333
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma.
Lee SJ; Song CM; Ji YB; Choi YY; Sohn YS; Park JH; Kim DS; Tae K
Langenbecks Arch Surg; 2021 Jun; 406(4):1223-1231. PubMed ID: 33970335
[TBL] [Abstract][Full Text] [Related]
14. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
15. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
16. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
17. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
[TBL] [Abstract][Full Text] [Related]
18. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
[TBL] [Abstract][Full Text] [Related]
19. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
[TBL] [Abstract][Full Text] [Related]
20. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?
Cox C; Bosley M; Southerland LB; Ahmadi S; Perkins J; Roman S; Sosa JA; Carneiro-Pla D
Surgery; 2018 Jan; 163(1):75-80. PubMed ID: 29122328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
